EA201692460A1 - Антитела, направленные на cd127 - Google Patents

Антитела, направленные на cd127

Info

Publication number
EA201692460A1
EA201692460A1 EA201692460A EA201692460A EA201692460A1 EA 201692460 A1 EA201692460 A1 EA 201692460A1 EA 201692460 A EA201692460 A EA 201692460A EA 201692460 A EA201692460 A EA 201692460A EA 201692460 A1 EA201692460 A1 EA 201692460A1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
antibodies
site
sequence
increase
Prior art date
Application number
EA201692460A
Other languages
English (en)
Other versions
EA039303B1 (ru
Inventor
Николя Пуарье
Каролин Мари
Бернард Ванхов
Original Assignee
Осе Иммунотерапеутикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52434718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201692460(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Осе Иммунотерапеутикс filed Critical Осе Иммунотерапеутикс
Publication of EA201692460A1 publication Critical patent/EA201692460A1/ru
Publication of EA039303B1 publication Critical patent/EA039303B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

Настоящее изобретение относится к антителам, которые направлены на CD127, альфа-цепь рецептора (IL-7R) интерлейкина 7 (IL-7) и которые характеризуются антагонистическими свойствами в отношении взаимодействия IL-7-IL-7R, могут проявлять цитотоксическую активность в отношении CD127-положительных клеток, но не повышают созревание дендритных клеток (DC), индуцируемое TSLP, цитокином, также использующим CD127 в составе своего рецептора. В качестве альтернативы или дополнения эти антитела не индуцируют интернализацию CD127 и/или ингибируют индуцируемую IL-7 интернализацию CD127. В соответствии с другим аспектом настоящего изобретения предполагаются антитела, которые распознают эпитоп человеческого CD127, содержащий последовательности из сайта 2b в CD127, в частности эпитоп, содержащий последовательности человеческого CD127 из домена D1 и из сайта 2b в CD127, в частности эпитоп содержит по меньшей мере одну последовательность из D1, содержащую SEQ ID No: 115 (в частности, содержащую SEQ ID No: 110) и/или SEQ ID No: 111, и/или последовательность из сайта 2b, содержащую последовательность SEQ ID No: 116, и необязательно также содержит SEQ ID No: 117 (в частности, содержит SEQ ID No: 111). Соответственно, антитела в соответствии с настоящим изобретением являются подходящими для применения с целью излечения состояния, диагностируемого у пациента-человека, которое является результатом патогенеза, связанного с лимфопоэзом, когда пути передачи сигнала с участием IL-7 вносят вклад в указанный патогенез, в особенности, когда нежелательным является повышение созревания дендритных клеток, более точно повышение экспрессии костимулирующих молекул в них.
EA201692460A 2014-06-10 2015-06-10 Антитела, направленные на cd127 EA039303B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010117P 2014-06-10 2014-06-10
EP15305078.6A EP2955196A1 (en) 2014-06-10 2015-01-23 Antibodies directed against CD127
PCT/EP2015/062993 WO2015189302A1 (en) 2014-06-10 2015-06-10 Antibodies directed against cd127

Publications (2)

Publication Number Publication Date
EA201692460A1 true EA201692460A1 (ru) 2017-04-28
EA039303B1 EA039303B1 (ru) 2022-01-11

Family

ID=52434718

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692460A EA039303B1 (ru) 2014-06-10 2015-06-10 Антитела, направленные на cd127

Country Status (26)

Country Link
US (3) US10428152B2 (ru)
EP (2) EP2955196A1 (ru)
JP (2) JP7324565B2 (ru)
KR (1) KR102612930B1 (ru)
CN (1) CN106715471B (ru)
AP (1) AP2016009599A0 (ru)
AU (1) AU2015273532C1 (ru)
BR (1) BR112016028755B1 (ru)
CA (1) CA2950823A1 (ru)
CL (1) CL2016003172A1 (ru)
CR (1) CR20160576A (ru)
EA (1) EA039303B1 (ru)
HK (1) HK1231487A1 (ru)
IL (1) IL249449B (ru)
MA (1) MA40202A (ru)
MX (1) MX2016016236A (ru)
MY (1) MY190889A (ru)
NZ (1) NZ726932A (ru)
PE (1) PE20170324A1 (ru)
PH (1) PH12016502445A1 (ru)
RU (1) RU2734076C2 (ru)
SA (1) SA516380455B1 (ru)
SG (1) SG11201610036PA (ru)
TN (1) TN2016000528A1 (ru)
UA (1) UA125366C2 (ru)
WO (1) WO2015189302A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
KR20180118746A (ko) 2016-02-29 2018-10-31 오제 이뮈노테라프틱스 Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도
PE20191152A1 (es) 2016-12-09 2019-09-05 Ose Immunotherapeutics Anticuerpos y polipeptidos dirigidos contra cd127
WO2019043065A1 (en) * 2017-08-29 2019-03-07 Ose Immunotherapeutics METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS
CN110117325B (zh) * 2018-03-09 2023-06-20 重庆市畜牧科学院 一种猪cd127多肽及其编码基因和应用
BR112021014106A2 (pt) 2019-01-22 2021-10-13 Bristol-Myers Squibb Company Anticorpos contra subunidade alfa de il-7r e usos dos mesmos
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986571A1 (en) * 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
CN114555643A (zh) 2019-06-21 2022-05-27 索瑞索制药公司 组合物
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2023232826A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarkers of il7r modulator activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AU2007266450A1 (en) 2006-05-31 2007-12-06 The Regents Of The University Of California CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
KR20130028055A (ko) * 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
TWI552760B (zh) 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗－ｉｌ－７受體抗體及方法
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
KR20180118746A (ko) 2016-02-29 2018-10-31 오제 이뮈노테라프틱스 Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도

Also Published As

Publication number Publication date
JP2017522903A (ja) 2017-08-17
MX2016016236A (es) 2017-07-05
CA2950823A1 (en) 2015-12-17
EA039303B1 (ru) 2022-01-11
RU2016151265A3 (ru) 2019-02-08
CR20160576A (es) 2017-05-08
US20190382497A1 (en) 2019-12-19
US20230340133A1 (en) 2023-10-26
HK1231487A1 (zh) 2017-12-22
JP2021184731A (ja) 2021-12-09
KR102612930B1 (ko) 2023-12-13
SA516380455B1 (ar) 2020-12-22
US11440964B2 (en) 2022-09-13
PE20170324A1 (es) 2017-04-01
CL2016003172A1 (es) 2017-07-14
BR112016028755B1 (pt) 2024-01-16
KR20170019417A (ko) 2017-02-21
CN106715471B (zh) 2021-04-09
SG11201610036PA (en) 2016-12-29
WO2015189302A1 (en) 2015-12-17
AU2015273532A1 (en) 2016-12-22
US10428152B2 (en) 2019-10-01
UA125366C2 (uk) 2022-03-02
CN106715471A (zh) 2017-05-24
AU2015273532C1 (en) 2021-07-15
RU2016151265A (ru) 2018-07-18
NZ726932A (en) 2022-02-25
AU2015273532B2 (en) 2021-03-04
IL249449A0 (en) 2017-02-28
MA40202A (fr) 2017-04-19
BR112016028755A2 (pt) 2017-11-14
RU2734076C2 (ru) 2020-10-12
MY190889A (en) 2022-05-17
IL249449B (en) 2020-06-30
PH12016502445A1 (en) 2017-03-06
EP3155014A1 (en) 2017-04-19
EP2955196A1 (en) 2015-12-16
TN2016000528A1 (en) 2018-04-04
US20170129959A1 (en) 2017-05-11
AP2016009599A0 (en) 2016-11-30
JP7324565B2 (ja) 2023-08-10

Similar Documents

Publication Publication Date Title
EA201692460A1 (ru) Антитела, направленные на cd127
SV2018005614A (es) Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2017001599A (es) Anticuerpos novedosos y sus usos.
CY1117650T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
MX2017003535A (es) Anticuerpos anti-glucagon y sus usos.
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201691541A1 (ru) Новые анти-baff антитела
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
EA201691853A1 (ru) Агонисты мускариновых рецепторов
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
EA201390813A1 (ru) Антитела и их применение
MX2021003555A (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201890149A1 (ru) Композиции криопреципитатов и способы их получения
EA202190094A1 (ru) Антитела против cd40 для применения в лечении аутоиммунного заболевания
EA201891710A1 (ru) Терапевтические соединения
CL2018000317A1 (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica
PH12019502694A1 (en) Anti-trkb antibodies